SUNNYVALE, Calif.–(BUSINESS WIRE)–HPE (NYSE: HPE) today announced a $1.2 billion order from Vultr, the world’s largest privately-held cloud infrastructure company, to deploy AMD Helios™ AI Rack by HPE systems at Vultr’s cloud data center locations in the United States. It is HPE’s first order for the new AMD Helios system, which features purpose-built HPE Networking scale-up switching and software. HPE and AMD will support Vultr’s effort to meet service provider and enterprise demand for mode

SUNNYVALE, Calif.–(BUSINESS WIRE)–HPE (NYSE: HPE) today announced a $1.2 billion order from Vultr, the world’s largest privately-held cloud infrastructure company, to deploy AMD Helios™ AI Rack by HPE systems at Vultr’s cloud data center locations in the United States. It is HPE’s first order for the new AMD Helios system, which features purpose-built HPE Networking scale-up switching and software. HPE and AMD will support Vultr’s effort to meet service provider and enterprise demand for mode

SUNNYVALE, Calif.–(BUSINESS WIRE)–HPE (NYSE: HPE) today is hosting HPE Networking Investor Day, where Networking business leaders will outline a strategy designed to accelerate profitable growth and long-term shareholder value creation in the AI era. The company will share how HPE plans to capture expansive demand across Data Center Networking, Routing, Campus & Branch, and Security, positioning HPE Networking as a key driver of its growth. “AI is reshaping the technology stack, making th

SUNNYVALE, Calif.–(BUSINESS WIRE)–HPE (NYSE: HPE) today is hosting HPE Networking Investor Day, where Networking business leaders will outline a strategy designed to accelerate profitable growth and long-term shareholder value creation in the AI era. The company will share how HPE plans to capture expansive demand across Data Center Networking, Routing, Campus & Branch, and Security, positioning HPE Networking as a key driver of its growth. “AI is reshaping the technology stack, making th

BOTHELL, Wash.–(BUSINESS WIRE)–Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for IM-1340, a potential first-in-class antibody-drug conjugate (ADC) for the treatment of advanced solid tumors.IM-1340 is designed to target a transport receptor with a unique tumor e

BOTHELL, Wash.–(BUSINESS WIRE)–Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for IM-1340, a potential first-in-class antibody-drug conjugate (ADC) for the treatment of advanced solid tumors.IM-1340 is designed to target a transport receptor with a unique tumor e

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.